debate on the use of mrd for multiple myeloma management
Published 6 years ago • 336 plays • Length 13:08Download video MP4
Download video MP3
Similar videos
-
11:23
challenges and future perspectives for minimal residual disease (mrd) in multiple myeloma
-
1:15
the importance of mrd in multiple myeloma management
-
2:24
the importance of mrd in multiple myeloma patients
-
0:52
mrd for multiple myeloma: is it ready for prime-time?
-
5:18
the value of mrd as a prognostic tool in myeloma
-
1:24:51
mds 2023: ps 2 - from clonal hematopoiesis to overt mds
-
7:39
understanding mrd
-
14:10
highlights in multiple myeloma: improving access to car-t therapy, novel targets & future outlooks
-
4:40
management of r/r myeloma and mrd assessment
-
3:01
the benefit of using mrd to guide treatment decisions in multiple myeloma
-
1:39
minimal residual disease (mrd) monitoring for multiple myeloma is here to stay
-
2:02
current approaches for the management of patients with high-risk multiple myeloma
-
1:33
the rise of mrd in multiple myeloma: could this be an answer to a cure?
-
2:57
when is the optimal time to measure minimal residual disease (mrd) in myeloma patients?
-
3:22
the main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
-
4:05
are we ready to use minimal residual disease (mrd) to direct multiple myeloma therapy?
-
8:42
assessing mrd in multiple myeloma
-
1:21
the value of sustained mrd negativity in mm
-
2:51
profiling deep minimal residual disease in multiple myeloma
-
2:17
mrd: a promising biomarker in multiple myeloma
-
3:28
the epigenetics of multiple myeloma and the rationale for hdac inhibitors
-
4:10
treatment-free intervals for patients with myeloma